Anna Kenney

TL;DR: Somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas are reported, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Groups 4, which suggest future avenues for rational, targeted therapy.

TL;DR: Up-regulation of the oncogenic transcriptional coactivator yes-associated protein 1 (YAP1), which is negatively regulated by the Hippo pathway, is reported in human medulloblastomas with aberrant Shh signaling, implicate YAP1 as a new Shh effector that may be targeted by medullOBlastoma therapies aimed at eliminating medulloplastoma recurrence.

TL;DR: The results show the importance of Mycn as a therapeutic target in established tumors in vivo, offer a mechanistic rationale to test PI3K inhibitors in MYCN-amplified neuroblastoma, and represent a therapeutic approach applicable to a broad range of cancers in which transcription factors are stabilized through aPI3K-dependent mechanism.

TL;DR: It is reported that YAP accelerates tumor growth and confers radioresistance, promoting ongoing proliferation after radiation, and indicates the YAP/IGF2/Akt axis as a therapeutic target in medulloblastoma.

TL;DR: It is shown that TAM numbers in patients are associated with better prognosis and that, consistently, in a murine model of medulloblastoma, these TAMs have anti-tumoural properties.